Pub. Date : 2019 Jun 25
PMID : 31056264
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A novel mechanism of irinotecan targeting MDM2 and Bcl-xL. | Irinotecan | BCL2 like 1 | Homo sapiens |
| 2 | In this study, we present a new mechanism of Irinotecan which inhibits the activities of MDM2, an E3 ligase of tumour suppressor p53, and Bcl-xL, an anti-apoptotic protein, through direct binding. | Irinotecan | BCL2 like 1 | Homo sapiens |
| 3 | In our structure modelling study, Irinotecan could fit to the binding sites of MDM2 and Bcl-xL for their known drugs, Nutlin-3 and ABT-737, with a better binding affinity than to Topo I. | Irinotecan | BCL2 like 1 | Homo sapiens |
| 4 | We further showed that Irinotecan increased the amount of p53 only in the presence of MDM2 and inhibited the physical interaction of Bcl-xL with Bim, a core pro-apoptotic protein. | Irinotecan | BCL2 like 1 | Homo sapiens |
| 5 | Collectively, we suggest a new mechanism of action for Irinotecan as a dual target inhibitor of MDM2 and Bcl-xL facilitating the anticancer activities mediated by p53 and Bcl-xL interaction partners. | Irinotecan | BCL2 like 1 | Homo sapiens |
| 6 | Collectively, we suggest a new mechanism of action for Irinotecan as a dual target inhibitor of MDM2 and Bcl-xL facilitating the anticancer activities mediated by p53 and Bcl-xL interaction partners. | Irinotecan | BCL2 like 1 | Homo sapiens |